- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approved September 28, 2023; EMA approved).
- Why 4/10
- OPFOLDA is already FDA-approved (September 28, 2023) and commercially marketed; there is no pending PDUFA, pivotal readout, or AdComm in the next 12 months. As an approved drug with no imminent binary regulatory catalyst, per the rubric the impactScore is capped at 3-5. It is one of several commercial products in BioMarin's diversified portfolio, not a single-asset binary, so the score is set at 4.
OPFOLDA (as part of POMBILITI + OPFOLDA) is already approved and generating revenue for BioMarin. The next catalyst to watch is the commercial ramp: quarterly revenue growth and market share gains against Sanofi's Nexviazyme in the Pompe disease market. BioMarin's Q3 2026 earnings (reported Nov 2, 2026) showed POMBILITI + OPFOLDA benefiting from supply constraints on competing therapies, but full-year guidance was trimmed slightly. No binary regulatory catalyst is scheduled.
Price Chart
Executive Summary
OPFOLDA (miglustat) is an oral enzyme stabilizer used in combination with POMBILITI (cipaglucosidase alfa-atga, an IV enzyme replacement therapy) for adults with late-onset Pompe disease. The FDA approved the combination on September 28, 2023. Originally developed by Amicus Therapeutics, the drug was acquired by BioMarin Pharmaceutical (NASDAQ: BMRN) through a $4.8 billion all-cash acquisition completed April 27, 2026. OPFOLDA is already commercialized in the U.S. and Europe, competing primarily with Sanofi's Nexviazyme. Five-year Phase 3 extension data presented in October 2026 showed durable efficacy. For a non-medical investor, OPFOLDA is a revenue-generating asset within BioMarin's broader rare-disease portfolio, with no pending binary regulatory catalyst; the investment thesis hinges on commercial execution and market share growth.
How It Works
OPFOLDA (miglustat) is an enzyme stabilizer taken as an oral capsule. In Pompe disease, patients lack a working enzyme that breaks down glycogen (a stored sugar) in muscle cells, causing muscle weakness and breathing problems. OPFOLDA is designed to stabilize the replacement enzyme (POMBILITI, given by IV infusion) in the bloodstream, keeping it active longer so it can reach muscle tissue and break down glycogen more effectively. It is always used together with POMBILITI as a two-component therapy.
Trial Status
OPFOLDA (with POMBILITI) was approved by the FDA in September 2023 based on the Phase 3 PROPEL study (NCT03729362). Five-year open-label extension data (ATB200-07; NCT04138277) were presented at the World Muscle Society congress in October 2026, showing durable efficacy: ERT-naive patients improved six-minute walk distance by +10.5% at year 5, and ERT-experienced patients stabilized (+0.7%).
The Two-Sided Case
Upcoming Catalysts
- Quarterly revenue growth and commercial uptake updates (next: Q4 2026 / full-year 2026 earnings, expected early February 2027)
- Potential label expansion or pediatric indication (no publicly announced filing as of November 2026)
- Market share dynamics versus Sanofi's Nexviazyme in the Pompe disease market
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report